Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Pazopanib, a multitargeted tyrosine kinase inhibitor, is recommended as the standard treatment for refractory soft tissue sarcoma (STS). However, there are comparatively few molecular determinants for predicting pazopanib efficacy. |